Altamira Therapeutics (NASDAQ:CYTO) entered into an agreement with Avernus Pharma of Dubai for the marketing and distribution of Bentrio, Altamira’s nasal spray for protection against airborne viruses and allergens, in the United Arab Emirates, Saudi Arabia, Kuwait, Qatar, Oman and Bahrain.
Under the accord, Avernus will start promoting and selling Bentrio in those markets after registration of Bentrio with the regulatory agencies in the territories.
“Avernus has a strong footprint and great network for the distribution of innovative medical device and drug products in the Middle East, and we very much look forward to working with their team,” Thomas Meyer, Altamira’s founder, chairman and CEO, said in a statement.
“We expect to see first sales in the region beginning in 2022,” he added.
